In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
Biomarin Pharmaceutical Inc (NASDAQ: BMRN) closed the day trading at $54.1 down -0.07% from the previous closing price of $54.14. In other words, the price has decreased by -$0.07 from its previous closing price. On the day, 1.46 million shares were traded. BMRN stock price reached its highest trading level at $54.55 during the session, while it also had its lowest trading level at $53.78.
Ratios:
For a better understanding of BMRN, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 8.15 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 16.62. For the most recent quarter (mrq), Quick Ratio is recorded 3.49 and its Current Ratio is at 5.52. In the meantime, Its Debt-to-Equity ratio is 0.11 whereas as Long-Term Debt/Eq ratio is at 0.10.
On November 15, 2024, Wolfe Research started tracking the stock assigning a Outperform rating and target price of $95.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on May 20 ’25 when Burkhart Erin sold 1,786 shares for $59.31 per share. The transaction valued at 105,928 led to the insider holds 14,173 shares of the business.
Burkhart Erin bought 1,786 shares of BMRN for $105,928 on May 20 ’25. On May 02 ’25, another insider, Hubbard Cristin, who serves as the EVP, Chief Commercial Officer of the company, sold 273 shares for $64.92 each. As a result, the insider received 17,723 and left with 32,700 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BMRN now has a Market Capitalization of 10382708736 and an Enterprise Value of 9704687616. As of this moment, Biomarin’s Price-to-Earnings (P/E) ratio for their current fiscal year is 20.07, and their Forward P/E ratio for the next fiscal year is 12.94. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.60. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.55 while its Price-to-Book (P/B) ratio in mrq is 1.79. Its current Enterprise Value per Revenue stands at 3.289 whereas that against EBITDA is 12.031.
Stock Price History:
The Beta on a monthly basis for BMRN is 0.17, which has changed by -0.34288836 over the last 52 weeks, in comparison to a change of 0.12463009 over the same period for the S&P500. Over the past 52 weeks, BMRN has reached a high of $94.85, while it has fallen to a 52-week low of $52.93. The 50-Day Moving Average of the stock is -7.66%, while the 200-Day Moving Average is calculated to be -17.15%.
Shares Statistics:
Over the past 3-months, BMRN traded about 2.09M shares per day on average, while over the past 10 days, BMRN traded about 2106570 shares per day. A total of 191.76M shares are outstanding, with a floating share count of 189.06M. Insiders hold about 1.42% of the company’s shares, while institutions hold 98.02% stake in the company. Shares short for BMRN as of 1749772800 were 4417385 with a Short Ratio of 2.11, compared to 1747267200 on 4449835. Therefore, it implies a Short% of Shares Outstanding of 4417385 and a Short% of Float of 2.9499999999999997.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The firm’s stock currently is rated by 20.0 analysts. The consensus estimate for the next quarter is $1.04, with high estimates of $1.29 and low estimates of $0.51.
Analysts are recommending an EPS of between $4.59 and $3.84 for the fiscal current year, implying an average EPS of $4.31. EPS for the following year is $5.4, with 22.0 analysts recommending between $6.46 and $4.47.
Revenue Estimates
21 analysts predict $761.51M in revenue for the current quarter. It ranges from a high estimate of $778M to a low estimate of $741M. As of the current estimate, Biomarin Pharmaceutical Inc’s year-ago sales were $712.03MFor the next quarter, 21 analysts are estimating revenue of $798.31M. There is a high estimate of $848.1M for the next quarter, whereas the lowest estimate is $746.1M.
A total of 27 analysts have provided revenue estimates for BMRN’s current fiscal year. The highest revenue estimate was $3.2B, while the lowest revenue estimate was $3.09B, resulting in an average revenue estimate of $3.14B. In the same quarter a year ago, actual revenue was $2.85BBased on 26 analysts’ estimates, the company’s revenue will be $3.45B in the next fiscal year. The high estimate is $3.7B and the low estimate is $3.2B.
